放化療聯合
頁數
文章編號
文章題目
354
P1.12-10
Patterns of curative chemo-radiotherapy regimen and impacts on the outcome of limited stage sclc in a canadian institution: 2010–2015 diagnoses
加拿大某機構化放療模式及對局限期小細胞肺癌預後的影響：2010-2015年的診斷病例
456
P2.01-49
Comparision of radiotherapy concurrent weekly treatment in locally advanced unresectablenon small cell lung cancer
局部進展期不可切除非小細胞肺癌放療同期不同周療方案的療效對比
616
P2.17-10
Daily low–dose cisplatin and high dose radiotherapy for elderly patients with stage III NSCLC is well tolerated
每日低劑量順鉑和高劑量放療對III期老年NSCLC耐受性良好
620
P2.17-20
Systematic literature review of chemoradiotherapy versus radiotherapy alone in elderly patients with stage III non-small cell lung cancer
III期非小細胞肺癌老年患者化放療和單純放療的系統性文獻綜述
624
P2.17-28
Real-world data: survival outcomes of chemotherapy regimens given concurrently with radiotherapy for locally advanced NSCLC
真實世界數據：局部進展期NSCLC同步放化療不同化療方案生存結果
774
P3.17-03
Survival and side effects in non-small cell lung cancer patients treated with combination of chemotherapy and conformal radiotherapy
化療聯合適形放療治療非小細胞肺癌患者的生存和副作用
775
P3.17-07
The beneficial effect of the high dose irradiation during concurrent chemoradiotherapy in locoregional advanced non-small cell lung cancer
局部進展期非小細胞肺癌同步放化療期間高劑量照射的獲益
放/化療+手術
36
MTE23.02
Surgical considerations following induction therapy for stage IIIa disease
IIIa期NSCLC誘導治療後的外科思考
56
PC08.05
Debate#2:Keep calm and beam on: thoracic radiation obviates the need for surgery
辯論2：保持冷靜和微笑：胸部放療後不再需要手術治療
129
OA06.06
Missile-NSCLC: a phase II trial measuring the integration of stereotactic radiotherapy plus surgery in early-stage non-small cell lung cancer
Missile-NSCLC：一項評估立體定向放療聯合手術治療早期非小細胞肺癌的II期試驗
225
MA23.05
Post-operative radiation improves overall survival in patients with node-positive non-small cell lung cancer undergoing sublobar resections
淋巴；結陽性非小細胞肺癌亞肺葉切除術後放療可延長總生存期
599
P2.16-16
SABRTOOTH: A fasibility study of SABR versus surgery in patients with peripheral stage I NSCLC considered to be at higher risk for surgery
SABRTOOTH：一項真實世界研究-手術高風險的I 期周圍型非小細胞肺癌患者SABR與手術切除療效對比
613
P2.17-03
A propensity-matched analysis of neoadjuvantchemoradiotherapy and adjuvant chemoradiotherapy for IIIa(N2) non-small cell lung cancer
IIIa期（N2）非小細胞肺癌新輔助放化療和輔助放化療的傾向匹配分析
658
P3.01-89
Upfront surgery versus neoadjuvant treatment followed by surgery in pathologic N2 non-small cell lung cancer
病理N2期非小細胞肺癌先行外科手術與新輔助治療+手術的療效對比
761
P3.16-12
Standard conventional lobectomy vs stereotactic body radiotherapy in patients with early stage non-small cell lung cancer (NSCLC) – a review
早期非小細胞肺癌（NSCLC）患者的標傳統肺葉切除術與立體定向放療的對比 - 綜述
放療+靶向治療
652
P3.01-68
Early SBRT to the primary tumor may overcome the icotinib resistance in patients with advanced NSCLC harboring EGFR mutations
原發腫瘤早期行SBRT可能會克服EGFR突變的進展期非小細胞肺癌患者埃克替尼耐藥問題
734
P3.13-10
Factors associated with long-term survival of stage IV NSCLC patients on first-line EGFR-targeting therapy
一線EGFR靶向治療的IV 期NSCLC患者的長期生存相關因素
755
P3.15-30
Treatment patterns and survival of patients with stage IV non-small cell lung cancer (NSCLC) in the era of novel therapies
新型治療時代IV非小細胞肺癌患者的治療模式和生存情況
782
P3.CR-02
SBRT of lung primary after complete resolution of metastatic disease in case of EGFR mutated adenocarcinoma lung: a case report
EGFR突變的肺腺癌患者轉移性病灶完全緩解後肺原發灶的立體定向放療：個案報導
放療+免疫治療
2
PL02.01
Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: updated results from PACIFIC
III期NSCLC患者放化療後應用durvalumab與安慰劑總生存的對比：PACIFIC研究更新結果
100
MS28.05
Combining IO with radiation
免疫治療聯合放療
130
OA07.01
Phase II study of pembrolizumab for oligometastatic non-small cell lung cancer (NSCLC) following completion of locally ablative therapy (LAT)
寡轉移非小細胞肺癌（NSCLC）局部消融治療後應用帕姆單抗的II期研究
156
MA04.01
Cemiplimab, a human monoclonal anti-pd-1, alone or in combination with radiotherapy: phase 1 NSCLC expansion cohorts
人單克隆PD-1抗體Cemiplimab單獨或聯合放療治療非小細胞肺癌：Ⅰ期擴大隊列研究
247
P1.01-07
Immune-related pneumonitis in NSCLC patients treated with immune checkpoint inhibitors (ICI): impact of previous thoracic radiotherapy
先期胸部放射治療對免疫檢查點抑制劑(ICI)治療NSCLC患者免疫相關性肺炎的影響
255
P1.01-24
Clinical efficacy of immunotherapy in metastatic non-small cell lung cancer patients treated with prior radiotherapy
轉移性非小細胞肺癌放療後免疫治療的臨床療效觀察
509
P2.04-25
Randomized clinical trial comparing immunotherapy plus SABR (I-SABR) versus SABR alone for early stage NSCLC
對比免疫治療加SABR (I-SABR)和單獨SABR治療早期NSCLC的隨機臨床試驗
胸部放療
36
MTE24.02
Small lung tumours: high risk lesions and contraindications to stereotactic ablative body radiotherapy (SABR)
肺部小腫瘤：SABR的高危部位和禁忌症
38
MTE27.01
Radiotherapy in ES-SCLC
廣泛期小細胞肺癌的放療
42
GR02.01
CASE 1: Single zone N2 (no pneumonectomy necessary)
病例1：單區域N2（無需肺切除術）
47
PC02.03
BID RADIATION – CON
每日2次放療--反對
47
PC02.04
BID RADIATION –PRO
每日2次放療--贊成
85
MS20.02
The future of stereotactic ablative radiotherapy (SABR)
SABR的未來方向
88
MS21.03
Revolution in Radiation
放療技術革新
148
MA01.09
Risk factors of radiation-induced lymphopenia (RIL) and its prognostic significance in small lung cancer patients treated with stereotactic body radiation therapy
小肺癌患者立體定向放療中放射性淋巴細胞減少的危險因素及其對預後的影響
148
MA01.10
Toxicity and local control in 「ultra- central」 lung tumors treated with SBRT or high-dose hypofractionated RT
SBRT或高劑量大分割放療治療「超中心型」肺部腫瘤的毒副作用和局控
148
MA01.11
Salvage SBRT for local recurrence after primary surgical resection of early stage non-small cell lung cancer
早期非小細胞肺癌手術切除後局部復發的挽救性SBRT
226
MA23.07
Defining the role of adjuvant therapy for early stage large cell neuroendocrine lung cancer
輔助治療在早期大細胞神經內分泌肺癌治療中的價值
353
P1.12-07
Time to the end of thoracic radiotherapy affects to survival outcomes greater than radiation dose in limited stage small cell lung cancer
胸部放療完成時間對局限期小細胞肺癌生存結果的影響大於放療劑量對生存結果的影響
559
P2.12-13
Effectiveness of hypofractionated thoracic radiotherapy in limited-stage small-cell lung cancer: a propensity score analysis
胸部大分割放療在局限期小細胞肺癌中的療效:傾向評分分析
561
P2.12-18
Interstitial lung abnormalities are a risk factor for radiation pneumonitis in patients with limited-stage small-cell lung cancer
肺間質異常是局限期小細胞肺癌患者放射性肺炎的危險因素
598
P2.16-14
Results of stereotactic radiation therapy (SABR) in early stage lung cancer: turkishradiation oncology group (TROG) study
早期肺癌中SABR的療效：土耳其放射腫瘤學組（TROG）研究結果
598
P2.16-15
Toxicities and survival after stereotactic ablative radiotherapy (SABR) for centrally located lung tumors
中央型肺腫瘤SABR的毒副作用和生存分析
599
P2.16-17
Hypo-fractionated accelerated radiotherapy in central early non-small cell lung cancer: LEEDS cancer centre experience
早期中央型非小細胞肺癌的加速大分割放療：LEEDS癌症中心的經驗
601
P2.16-22
Comparing two common radiotherapy regimens in non-small cell lung cancer - a retrospective study
比較非小細胞肺癌的兩種常用放療策略 - 回顧性研究
761
P3.16-13
Long-term outcomes of stereotactic body radiation therapy for stage I non-small cell lung cancer in patients less than 70 years of age
小於70歲的 I 期非小細胞肺癌患者行立體定向放療的遠期療效分析
762
P3.16-16
Long term outcomes of body gamma-ray stereotactic ablative radiotherapy for patients with stage I/II non-small cell lung cancer
I / II期非小細胞肺癌γ刀治療的長期療效分析
763
P3.16-19
Clinical outcomes of stereotactic body radiation therapy for T2N0M0 non-small cell lung cancer
T2N0M0非小細胞肺癌立體定向放療的臨床療效
780
P3.17-19
First relapse and survival five years after radical radiotherapy for lung cancer
肺癌根治性放療後首次復發時間和5年生存率
腦部放療
57
PC08.07
Debate #3: Brain metastases with a driver mutation should be treated with systemic therapy first (PRO)
辯論：驅動基因突變的腦轉移患者應首先採用系統性治療（贊成）
58
PC09.01
Debate 1: Early vs delayed treatment of asymptomatic brain metastases in wild-type NSCLC - early
早期vs延遲治療野生型非小細胞肺癌無症狀性腦轉移
116
OA01.01
10-year updated analysis of NRG oncology/RTOG 0214: a phase III comparison of PCI vs observation in patients with LA-NSCLC
NRG oncology/RTOG 0214研究10年數據更新：局部進展期NSCLC患者預防性腦照射對比觀察的一項III期試驗
144
OA13.05
Prophylactic cranial irradiation (PCI) for limited- stage small-cell lung cancer: results from the phase 3 convert trial
局限期小細胞肺癌預防性腦照射：3期轉換性試驗結果
144
OA13.07
Survival outcomes after whole brain radiotherapy for brain metastases in elderly patients with newly diagnosed metastatic small cell carcinoma
新診斷的老年小細胞肺癌腦轉移患者行全腦放療後的生存分析
170
MA08.01
Phase 3 trial of whole brain radiotherapy with concurrent erlotinib versus WBRT alone for NSCLC with brain metastases (enter)
WBRT聯合厄洛替尼對比WBRT治療NSCLC腦轉移的III期試驗
170
MA08.02
Prophylactic cranial irradiation reduces the risk of brain metastases in high-risk lung cancer patients: EGFR and ALK mutations
預防性腦照射可降低EGFR和ALK突變的高危肺癌患者的腦轉移風險
171
MA08.03
EGFR-TKI plus brain radiotherapy versus EGFR-TKI alone in the management of EGFR mutated NSCLC patients with brain metastases: a meta-analysis
EGFR-TKI聯合顱腦放療對比單純EGFR-TKI治療EGFR突變的非小細胞肺癌腦轉移患者：一項Meta分析
173
MA08.11
Early safety data of a phase I/II combining nivolumab and stereotactic brain radiosurgery for treatment of brain metastases in patients with NSCLC
納武單抗聯合腦立體定向放療治療非小細胞肺癌腦轉移患者的I / II期早期安全性數據
223
MA22.09
Should stereotactic radiosurgery be considered for salvage of intracranial recurrence in small cell lung cancer?
小細胞肺癌顱內復發是否可考慮挽救性立體定向放療？
223
MA22.10
Prevalence and risk factors of brain metastases in limited stage small cell lung cancer immediately before prophylactic cranial irradiation
在預防性腦照射前即刻評估局限小細胞肺癌腦轉移的患病率和危險因素
223
MA22.11
Risk of hippocampal metastases in small cell lung cancer: implications for hippocampal sparing cranial irradiation
小細胞肺癌海馬保護性放療對海馬轉移風險的影響
244
P1.01-03
Effect of prophylactic cranial irradiation on cognitive function and QOL in NSCLC patients at high risk of brain metastases
預防性腦照射對非小細胞肺癌腦轉移高危患者的認知功能和生活質量的影響
358
P1.12-18
Outcome in small cell lung cancer patients with cerebral recurrence after prior prophylactic cranial irradiation
預防性腦照射後顱內復發的小細胞肺癌患者預後分析
284
P1.01-100
Concurrent brain radiotherapy and EGFR-TKI have better survival benefits in patients with brain metastases from EGFR-mutant NSCLC
顱腦放療聯合EGFR-TKI治療EGFR-突變型NSCLC腦轉移患者有更好的生存獲益
483
P2.01-124
SIB-IMRT in symptomatic brain metastases for NSCLC: a randomized controlled study of WBRT comparing 25Gy and 30Gy
SIB-IMRT治療有症狀的NSCLC腦轉移:WBRT 25Gy對比30Gy的隨機對照研究
484
P2.01-127
Efficacy of endostar combined with whole brain radiotherapy in patients with NSCLC brain metastases
恩度聯合全腦放療治療非小細胞肺癌腦轉移的療效觀察
560
P2.12-14
Stereotactic radiosurgery for brain metastases in small cell lung cancer
小細胞肺癌腦轉移的立體定向放療
561
P2.12-17
Prophylactic cranial irradiation can not provide survival benefits for resected small cell lung cancer without lymph node involvement
無淋巴結轉移的小細胞肺癌術後預防性腦照射未能提供生存獲益
561
P2.12-19
Prophylactic cranial irradiation in extensive small cell lung cancer: a meta-analysis of randomized controlled trials
廣泛期小細胞肺癌的預防性顱腦照射-基於隨機對照試驗的Meta分析
686
P3.04-22
Response of brain metastases in patients with non-small cell lung cancer treated with immunotherapy and brain directed radiotherapy
非小細胞肺癌腦轉移患者免疫治療聯合顱腦放療的反應
寡轉移
14
ES06.01
Current clinical trials in oligometastases
寡轉移相關的當前臨床試驗
61
MS03.05
Integration of immunotherapy in the oligometastatic paradigm
探討寡轉移病變放療和免疫治療的最佳組合方式
130
OA07.02
ATOM: A phase II study to assess efficacy of preemptive local ablative therapy to residual oligometastases afterEGFR TKI
ATOM：對EGFR TKI治療後殘存寡轉移灶早期行局部消融治療的II期療效評估
130
OA07.03
Addition of local therapy to EGFR-TKI showed survival benefit in EGFR-mutant NSCLC pts with oligometastatic or oligoprogressive liver metastases
EGFR-TKI治療寡進展或肝臟寡轉移的EGFR突變NSCLC患者中加入局部治療顯示生存效益
131
OA07.05
Local ablative therapy improves survival in patients with synchronous oligometastatic NSCLC harboring EGFR mutation treated with EGFR-TKIS
局部消融可以改善EGFR-TKIS治療的EGFR突變陽性的同時性寡轉移非小細胞肺癌患者的生存
131
OA07.06
Efficacy of local consolidative therapy for oligometastatic lung adenocarcinoma patients harboring EGFR mutations
局部鞏固治療對EGFR突變陽性的寡轉移肺腺癌患者的療效分析
235
MA25.07
Effectiveness of systemic therapy combined with thoracic radiotherapy for patients with oligometastatic NSCLC: a pooled analysis
系統性治療聯合胸部放療對寡轉移NSCLC患者的療效：一項匯總分析
653
P3.01-69
Stereotactic ablative radiotherapy improves progression-free survival & local control in oligometastatic lung cancer patients
立體定向放療可改善寡轉移肺癌患者的無進展生存期和局部控制率
695
P3.08-02
Oligometastatic non-small cell lung cancer patients treated with stereotactic body radiotherapy (SBRT), a single institution experience
非小細胞肺癌寡轉移患者立體定向體放療(SBRT)：單中心經驗
695
P3.08-03
Stereotactic radiotherapy of lung cancer with synchronous bilateral noduli or oligometastatic disease
同時雙側結節性或寡轉移性肺癌的立體定向放療
696
P3.08-05
Stereotactic body radiation therapy (SBRT) outcomes in elderly patients with lung oligometastases
老年寡轉移肺癌患者SBRT的療效分析
697
P3.08-07
An institution review of outcomes of lung stereotactic body radiotherapy in various oligometastatic disease states
立體定向放療治療不同寡轉移狀態的單中心回顧性療效分析
699
P3.08-13
Stereotactic body radiotherapy (SBRT) for oligometastatic lung nodules: a single institution series
立體定向放療(SBRT)治療寡轉移性肺結節：單中心分析
放療基礎研究
220
MA22.01
PARP inhibitor radiosensitization of small cell lung cancer differs by PARP trapping potency
PARP抑制劑對小細胞肺癌的放射增敏作用隨PARP捕獲效能而有所差異
241
MA27.02
Hypofractionated radiotherapy normalizes tumor vasculature in non-small cell lung cancer xenografts through P-STAT3/HIF-1 alpha pathway
大分割放療通過P-STAT3 / HIF-1 α途徑使非小細胞肺癌轉移瘤中的血管正常化
408
P1.16-18
Role of ERCC1/2 single nucleotide polymorphism (SNP) on treatment response in patients with lung cancer undergoing radiation therapy
ERCC1/2單核苷酸多態性(SNP)在肺癌患者放療反應中的治療反應
430
P1.17-03
Potential associated SNPs by GWAS with radiation pneumonitis (RP) in patients with lung cancer treated with radiotherapy
通過GWAS分析的單核苷酸多態性與放射性肺炎（RP）潛在關聯
432
P1.17-09
V30 may better predict radiation pneumonitis after intensity-modulated radiation therapy for lung cancer
V30可以更好地預測肺癌調強放療後的放射性肺炎
507
P2.04-18
The association between IDO activity and clinical prognosis in patients with non-small cell lung cancer after radiotherapy
非小細胞肺癌放療後IDO酶活性與臨床預後的關係
617
P2.17-12
Eliminating radiation resistance of non-small cell lung cancer by DHA trough abrogating immunity escaping via inhibiting pd-l1 expression
DHA通過抑制PD-L1表達消除免疫逃逸從而消除非小細胞肺癌的放射抗性
632
P3.01-14
MTORC1 regulates the radiosensitivity of NSCLC cells with wildtype PI3KCA and KRAS genes by affecting EMT
MTORC1通過影響EMT調節野生型PI3KCA和KRAS基因的NSCLC細胞的放射敏感性
650
P3.01-62
A new method for non-invasive prediction of radiotherapy: SDH5 depletion enhances radiosensitivity by regulating P53
一種新型非侵入性預測放療療效的方法：SDH5耗竭通過調節P53增強放射敏感性
677
P3.03-28
LKB1 Mutation status is associated with poor radiation outcome in patients with non-small cell lung cancer
LKB1突變狀態與非小細胞肺癌患者放療療效不佳相關
放射物理/技術
102
MS30.01
Overview of RT technology in LA-NSCLC(IMRT,VMAT, IGRT)
局部進展期NSCLC治療中的（IMRT，VMAT，IGRT）放療技術概述
116
OA01.02
The estimate of shrinking field and SIB radiotherapy guided by 18F-FDG PET/CT in locally advanced NSCLC patients: a phase 2 randomized clinical
18F-FDG PET/CT在局部進展期NSCLC患者中指導放療縮野和同期整合加量：2期隨機臨床試驗
116
OA01.03
Interaction between dose and calcifications is a predictor for overall survival in lung cancer patients receiving radiotherapy
放療劑量和鈣化的相互作用是肺癌放療患者總生存的預測因素
129
OA06.05
Do SBRT planning and delivery factors influence local control for early stage non-small cell lung cancer (E-NSCLC)?
SBRT計劃和實施因素是否對早期非小細胞肺癌（E-NSCLC）的局控有影響？
147
MA01.07
Validation of RTOG 0813 normal tissue constraints for pulmonary toxicity in SBRT for central non-small cell lung cancer.
RTOG 0813研究確定了中央型非小細胞肺癌SBRT治療中肺的正常組織限量
163
MA05.06
Locally advanced lung cancer radiotherapy in deep inspiration breath hold: dosimetric benefits from a prospective trial.
局部進展期肺癌放療採用在深吸氣末屏氣- 前瞻性試驗的劑量學優勢
163
MA05.07
Dose escalated CHEMO-RT to 84 Gy in stage III NSCLC appears excessively toxic: results from a randomized phase II trial
III期NSCLC放化療劑量增加至84 Gy出現過度毒副作用：一項隨機II期試驗的結果
164
MA05.10
The pathologic response of locally advanced NSCLC treated with concomitant chemoradiation to 60 Gy in image guided radiation therapy (IGRT)
局部進展期NSCLC同步化放療中應用圖像引導放療劑量至60 Gy時的病理反應
399
P1.15-29
Impact of radiation therapy quality assurance on progression-free and overall survival in randomized trials of lung cancer
在肺癌隨機試驗中，放療QA對無進展生存期和總生存期的影響
411
P1.16-26
Safety of SABR (stereotactic ablative body radiotherapy) for central non-small cell lung cancers (CNSCLC) with 50 gray in 5 fractions (50Gy/5f)
SABR 50Gy/5f 在中央型非小細胞肺癌治療中的安全性
412
P1.16-29
Accelerated hypofractionated radiotherapy for central lung tumors unsuitable for stereotactic body radiotherapy or concurrent CRT
中央型肺癌的加速分割放療並不適合採用立體定向放療或同步CRT
430
P1.17-05
Accelerated radiotherapy for non-small cell lung cancer: a 12 year retrospective review of two dose fractionation schedules
非小細胞肺癌加速放療: 兩種劑量分割策略的12年回顧
431
P1.17-07
The prognostic value of volumetric changes of the GTV measured on CBCT during radiotherapy for CCRT in NSCLC patients
非小細胞肺癌同步放化療過程中測量CBCT上GTV體積變化的預後價值
437
P1.17-19
Correlation of dosimetric and clinical factors with radiation pneumonitis in lung cancer patients received involved-field IMRT
採用累及野調強放療的肺癌患者放射性肺炎發生的劑量學與臨床相關因素
775
P3.17-06
Impact of integrating PET-CT in radiotherapy planning of non small cell carcinoma lung: dosimetric and radiobiological comparison
PET-CT參與制定非小細胞肺癌放療計劃的影響：劑量學和放射生物學比較